Business Wire

CEDO

20.9.2021 09:02:14 CEST | Business Wire | Press release

Share
Cedo Reveals Roadmap for Sustainable Business Growth

Cedo, one of Europe’s largest manufacturers of recycled plastic waste bags has today revealed its Roadmap for Sustainable Business Growth. The plan is built on three pillars: People, Planet and Products and comes with targets designed to protect the earth’s resources while attracting and nurturing talent within the business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005048/en/

“Our plan has been built with deep engagement from all the employees within our company,” says Rik De Vos, CEO of Cedo. “The journey to circularity will not be easy, but I have seen an immediate shift in decision making, and prioritisation of actions now that we are a purpose-led business. We are actively contributing to European and UK legislative debate to accelerate this transformation, while articulating and communicating proactively and transparently. A dream has been turned into a great journey and it pleases me enormously to see the response from everybody on our ambition.”

People

To better serve customers and employees, Cedo is committing to become positively involved in its communities in the seven countries in which it operates, investing in them both as an employer and community member while actively supporting local environmental, health and wellness projects.

With its industry-leading focus on sustainability and rewarding career and development opportunities, Cedo hopes to attract fresh and diverse talent to join its two thousand-strong workforce who are as committed to environmental sustainability as they are to innovation. “We recognise that our economic growth as a business can only be delivered by valued colleagues and communities, high quality products and a healthy planet. Our pillars are aligned to these beliefs. Real success can only come from delivering progress in all three areas,” De Vos said.

Planet

For planet, the business has committed to achieving climate neutrality across its global operations by 2030, increasing its use of renewable energy and improving energy efficiency usage.

Cedo will also improve its stewardship of water, with clear monitoring and improvement plans while reducing the overall water consumption in its operations. The business aims to send zero waste to landfill and has already achieved this target this year in the UK.

Product

To achieve circularity, Cedo has pledged to use only recycled, recyclable or sustainable materials for both packaging and product design. “We will use the Ellen MacArthur Foundation’s Circulytics measurement tool, transparently tracking its progress to become a circular business,” says Ton Emans, Director of Recycling at Cedo and President of Plastics Recyclers Europe. “We’ve been members of the Ellen MacArthur Foundation and participants of the New Plastics Economy initiative since its inception in 2016 and by working together we are confident that we can transition from a linear to a circular business model over the next few years.”

Working with customers in 34 countries and listening to their needs, Cedo is aiming to dramatically reduce plastics in its products and focus better on the use of raw materials through its eco-design process, selecting the appropriate raw material for each product and its intended life cycle. Going forward, the business will only purchase from suppliers which meet its ethical, environmental and social standards.

All of these steps that Cedo is taking towards sustainable business growth will be measured and shared in a new, fully transparent Grow With Purpose report, released every year.

Supporting nine of the United Nations Sustainable Development Goals

As well as outlining its approach to doing business, Cedo’s Roadmap for Sustainable Business Growth explains how it will work towards nine of the United Nations Sustainable Development Goals. These are Goal 3, Good Health and Well-Being; Goal 5, Gender Equality; Goal 8, Decent Work and Economic Growth; Goal 9, Industry, Innovation and Infrastructure; Goal 12, Responsible Consumption and Production; Goal 13, Climate Action; Goal 14, Life Below Water; Goal 15, Life On Land and Goal 16, Peace, Justice and Strong Institutions.

In July 2021, Cedo announced that it is one quarter of the way to achieving its 100 per cent renewable energy goal, which will see it becoming a climate neutral business by 2030.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye